KOSDAQ - Delayed Quote KRW

NKMAX CO., Ltd. (182400.KQ)

2,020.00 0.00 (0.00%)
At close: March 25 at 3:30 PM GMT+9
Key Events
Loading Chart for 182400.KQ
DELL
  • Previous Close 2,020.00
  • Open 0.00
  • Bid --
  • Ask --
  • Day's Range 2,020.00 - 2,020.00
  • 52 Week Range 1,550.00 - 8,205.00
  • Volume 0
  • Avg. Volume 7,189,268
  • Market Cap (intraday) 50.227B
  • Beta (5Y Monthly) 1.10
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date May 13, 2024 - May 17, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

NKMAX CO., Ltd. manufactures and sells biological products in South Korea. The company offers anti-cancer immunotherapy treatment that activates the immune cells in body to kill the cancer cells; natural killer cell activity test for cancer patients; NK VUE Kit, an NK cell activity test that quantitatively measures IFN-gamma released from activated NK cells with small amount of blood; and NK365, a proprietary blend of vitamins, minerals, and agaricus mushroom extract for immune system. It also provides recombinant proteins and monoclonal antibodies; and NK PUPPY, a test that measures dog's immunity. The company was formerly known as ATGen Co and changed name to NKMAX CO., Ltd. in 2019. NKMAX CO., Ltd. was founded in 2002 and is headquartered in Seongnam-si, South Korea.

www.nkmax.com

--

Full Time Employees

December 31

Fiscal Year Ends

--

Sector

--

Industry

Related News

Performance Overview: 182400.KQ

Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

182400.KQ
67.58%
KOSPI Composite Index
0.04%

1-Year Return

182400.KQ
63.83%
KOSPI Composite Index
6.90%

3-Year Return

182400.KQ
76.30%
KOSPI Composite Index
17.44%

5-Year Return

182400.KQ
73.07%
KOSPI Composite Index
21.89%

Compare To: 182400.KQ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 182400.KQ

Valuation Measures

Annual
As of
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    48.85%

  • Return on Assets (ttm)

    -21.47%

  • Return on Equity (ttm)

    -37.11%

  • Revenue (ttm)

    10.77B

  • Net Income Avi to Common (ttm)

    5.26B

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    914.97M

  • Total Debt/Equity (mrq)

    46.78%

  • Levered Free Cash Flow (ttm)

    -26.49B

Company Insights: 182400.KQ

People Also Watch